Legg Mason Starts Hollis-Eden Pharmaceuticals with 'Sell'

Analyst Edward Nash thinks the shares will be negatively affected if Hollis-Eden can't secure a government contract for its lead product

Legg Mason initiated coverage on Hollis-Eden Pharmaceuticals (HEPH ) with sell.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.